Sonelokimab in Psoriatic Arthritis

Trial
100%75%50%25%0%Jun 24Jun 25Jun 26Jun 27Jun 28Jun 29Jun 30Jul 1Jul 2Jul 3Jul 4Jul 5Jul 6Jul 7Jun 24 • YES 58.0%Jun 25 • YES 73.0%Jun 29 • YES 73.6%Jun 30 • YES 73.6%Jul 1 • YES 63.1%Jul 2 • YES 83.1%Jul 3 • YES 83.1%Jul 4 • YES 9.7%Jul 5 • YES 9.7%Jul 6 • YES 40.5%Jul 7 • YES 93.2%
ResolvedYES
Oracle Evidence
Resolved Date
10/1/26
Study Completion
2/4/27
Sponsor
MoonLake Immunotherapeutics
Ticker
$MLTX
Type
Phase 3
Trial Status
Active Not Recruiting
Trial Size
960
NCT
NCT06641076
Trial Description
Sonelokimab is being tested in biologic-naive psoriatic arthritis; this market resolves on Week 16 ACR50 success by Sept. 30, 2026.